PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.

Abstract Host-directed therapies that augment host immune effector mechanisms may serve as important adjunctive therapies for tuberculosis treatment. We evaluated the activity of denileukin diftitox in an acute mouse model of tuberculosis (TB) infection and analyzed the cellular composition and bacterial burden in lungs and spleens. These in vivo studies show that denileukin diftitox potentiates standard TB treatment in the mouse model, an effect which may be due to depletion of T-regulatory and myeloid-derived suppressor cells during TB infection. Our results indicate that denileukin diftitox and other suppressor cell-depleting therapies may be useful adjunctive, host-directed therapies for TB.
PMID
Related Publications

Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice.

Denileukin diftitox.

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.

Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.

Authors

Mayor MeshTerms
Keywords

Denileukin diftitox recombinant fusion protein toxin

Host-directed therapy

Immunotherapy

Tuberculosis

Journal Title the journal of infectious diseases
Publication Year Start




PMID- 28863467
OWN - NLM
STAT- MEDLINE
DA  - 20170902
DCOM- 20170907
LR  - 20170907
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 215
IP  - 12
DP  - 2017 Jun 15
TI  - Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective 
      Host-Directed Therapy for Tuberculosis.
PG  - 1883-1887
LID - 10.1093/infdis/jix208 [doi]
AB  - Host-directed therapies that augment host immune effector mechanisms may serve as
      important adjunctive therapies for tuberculosis treatment. We evaluated the
      activity of denileukin diftitox in an acute mouse model of tuberculosis (TB)
      infection and analyzed the cellular composition and bacterial burden in lungs and
      spleens. These in vivo studies show that denileukin diftitox potentiates standard
      TB treatment in the mouse model, an effect which may be due to depletion of
      T-regulatory and myeloid-derived suppressor cells during TB infection. Our
      results indicate that denileukin diftitox and other suppressor cell-depleting
      therapies may be useful adjunctive, host-directed therapies for TB.
CI  - (c) The Author 2017. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      [email protected]
FAU - Gupta, Shashank
AU  - Gupta S
AD  - Center for Tuberculosis Research, Department of Medicine, Johns Hopkins
      University, Baltimore, Maryland.
FAU - Cheung, Laurene
AU  - Cheung L
AD  - Center for Tuberculosis Research, Department of Medicine, Johns Hopkins
      University, Baltimore, Maryland.
FAU - Pokkali, Supriya
AU  - Pokkali S
AD  - Center for Tuberculosis Research, Department of Medicine, Johns Hopkins
      University, Baltimore, Maryland.
FAU - Winglee, Kathryn
AU  - Winglee K
AD  - Center for Tuberculosis Research, Department of Medicine, Johns Hopkins
      University, Baltimore, Maryland.
FAU - Guo, Haidan
AU  - Guo H
AD  - Center for Tuberculosis Research, Department of Medicine, Johns Hopkins
      University, Baltimore, Maryland.
FAU - Murphy, John R
AU  - Murphy JR
AD  - Center for Tuberculosis Research, Department of Medicine, Johns Hopkins
      University, Baltimore, Maryland.
AD  - National Emerging Infectious Diseases Laboratories Institute, Boston University, 
      Massachusetts.
FAU - Bishai, William R
AU  - Bishai WR
AD  - Center for Tuberculosis Research, Department of Medicine, Johns Hopkins
      University, Baltimore, Maryland.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Diphtheria Toxin)
RN  - 0 (Interleukin-2)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 25E79B5CTM (denileukin diftitox)
SB  - AIM
SB  - IM
MH  - Animals
MH  - Diphtheria Toxin/*therapeutic use
MH  - Disease Models, Animal
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Interleukin-2/*therapeutic use
MH  - Lung/immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mycobacterium tuberculosis/*immunology
MH  - Myeloid-Derived Suppressor Cells/*immunology
MH  - Recombinant Fusion Proteins/therapeutic use
MH  - Recombinant Proteins/therapeutic use
MH  - Spleen/immunology
MH  - T-Lymphocytes, Regulatory/*immunology
MH  - Tuberculosis/*therapy
OTO - NOTNLM
OT  - Denileukin diftitox recombinant fusion protein toxin
OT  - Host-directed therapy
OT  - Immunotherapy
OT  - Tuberculosis
EDAT- 2017/09/03 06:00
MHDA- 2017/09/08 06:00
CRDT- 2017/09/03 06:00
PHST- 2017/01/17 [received]
PHST- 2017/05/17 [accepted]
AID - 3858342 [pii]
AID - 10.1093/infdis/jix208 [doi]
PST - ppublish
SO  - J Infect Dis. 2017 Jun 15;215(12):1883-1887. doi: 10.1093/infdis/jix208.